On March 13, 2024, Anavex Life Sciences Corporation was sued for violations of the federal securities laws in the United States District Court for the Southern District of New York on behalf of investors who who purchased or
otherwise acquired Anavex stock between February 1, 2022 and January 1, 2024, inclusive (the “Class Period”).
We use cookies to improve your overall web experience. By using our website, you consent to the use of cookies in accordance with our Privacy Policy.